Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.
Identifieur interne : 001F10 ( Ncbi/Curation ); précédent : 001F09; suivant : 001F11Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.
Auteurs : Thibault Renoir [Australie] ; Andrew Argyropoulos [Australie] ; Caroline Chevarin [France] ; Laurence Lanfumey [France] ; Anthony J. Hannan [Australie]Source :
- Pharmacology, biochemistry, and behavior [ 1873-5177 ] ; 2014.
Descripteurs français
- KwdFr :
- Acide 3,4-dihydroxy-benzèneacétique (antagonistes et inhibiteurs), Acide 3,4-dihydroxy-benzèneacétique (métabolisme), Animaux, Caractères sexuels, Dopamine (métabolisme), Femelle, Inhibiteurs de la capture de la dopamine (pharmacologie), Inhibiteurs de la capture de la dopamine (usage thérapeutique), Maladie de Huntington (génétique), Maladie de Huntington (métabolisme), Maladie de Huntington (traitement médicamenteux), Modèles animaux de maladie humaine, Mâle, Récepteur dopamine D1 (antagonistes et inhibiteurs), Récepteur dopamine D1 (métabolisme), Souris, Souris de lignée C57BL, Souris de lignée CBA, Souris transgéniques.
- MESH :
- antagonistes et inhibiteurs : Acide 3,4-dihydroxy-benzèneacétique, Récepteur dopamine D1.
- génétique : Maladie de Huntington.
- métabolisme : Acide 3,4-dihydroxy-benzèneacétique, Dopamine, Maladie de Huntington, Récepteur dopamine D1.
- pharmacologie : Inhibiteurs de la capture de la dopamine.
- traitement médicamenteux : Maladie de Huntington.
- usage thérapeutique : Inhibiteurs de la capture de la dopamine.
- Animaux, Caractères sexuels, Femelle, Modèles animaux de maladie humaine, Mâle, Souris, Souris de lignée C57BL, Souris de lignée CBA, Souris transgéniques.
English descriptors
- KwdEn :
- 3,4-Dihydroxyphenylacetic Acid (antagonists & inhibitors), 3,4-Dihydroxyphenylacetic Acid (metabolism), Animals, Disease Models, Animal, Dopamine (metabolism), Dopamine Uptake Inhibitors (pharmacology), Dopamine Uptake Inhibitors (therapeutic use), Female, Huntington Disease (drug therapy), Huntington Disease (genetics), Huntington Disease (metabolism), Male, Mice, Mice, Inbred C57BL, Mice, Inbred CBA, Mice, Transgenic, Receptors, Dopamine D1 (antagonists & inhibitors), Receptors, Dopamine D1 (metabolism), Sex Characteristics.
- MESH :
- chemical , antagonists & inhibitors : 3,4-Dihydroxyphenylacetic Acid, Receptors, Dopamine D1.
- chemical , metabolism : 3,4-Dihydroxyphenylacetic Acid, Dopamine, Receptors, Dopamine D1.
- chemical , pharmacology : Dopamine Uptake Inhibitors.
- chemical , therapeutic use : Dopamine Uptake Inhibitors.
- drug therapy : Huntington Disease.
- genetics : Huntington Disease.
- metabolism : Huntington Disease.
- Animals, Disease Models, Animal, Female, Male, Mice, Mice, Inbred C57BL, Mice, Inbred CBA, Mice, Transgenic, Sex Characteristics.
Abstract
Using the R6/1 transgenic mouse model of Huntington's disease (HD), we have recently shown that acute administration with the dopamine-norepinephrine reuptake inhibitor bupropion was able to rescue depressive-like behaviours in female HD mice at 12weeks of age.
DOI: 10.1016/j.pbb.2014.10.004
PubMed: 25316307
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003254
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003144
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003144
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001F10
Links to Exploration step
pubmed:25316307Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.</title>
<author><name sortKey="Renoir, Thibault" sort="Renoir, Thibault" uniqKey="Renoir T" first="Thibault" last="Renoir">Thibault Renoir</name>
<affiliation wicri:level="4"><nlm:affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia. Electronic address: thibault.renoir@unimelb.edu.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Argyropoulos, Andrew" sort="Argyropoulos, Andrew" uniqKey="Argyropoulos A" first="Andrew" last="Argyropoulos">Andrew Argyropoulos</name>
<affiliation wicri:level="4"><nlm:affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chevarin, Caroline" sort="Chevarin, Caroline" uniqKey="Chevarin C" first="Caroline" last="Chevarin">Caroline Chevarin</name>
<affiliation wicri:level="1"><nlm:affiliation>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris</wicri:regionArea>
<wicri:noRegion>75013 Paris</wicri:noRegion>
<wicri:noRegion>75013 Paris</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lanfumey, Laurence" sort="Lanfumey, Laurence" uniqKey="Lanfumey L" first="Laurence" last="Lanfumey">Laurence Lanfumey</name>
<affiliation wicri:level="1"><nlm:affiliation>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris</wicri:regionArea>
<wicri:noRegion>75013 Paris</wicri:noRegion>
<wicri:noRegion>75013 Paris</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hannan, Anthony J" sort="Hannan, Anthony J" uniqKey="Hannan A" first="Anthony J" last="Hannan">Anthony J. Hannan</name>
<affiliation wicri:level="4"><nlm:affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25316307</idno>
<idno type="pmid">25316307</idno>
<idno type="doi">10.1016/j.pbb.2014.10.004</idno>
<idno type="wicri:Area/PubMed/Corpus">003254</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003254</idno>
<idno type="wicri:Area/PubMed/Curation">003144</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003144</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003144</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003144</idno>
<idno type="wicri:Area/Ncbi/Merge">001F10</idno>
<idno type="wicri:Area/Ncbi/Curation">001F10</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.</title>
<author><name sortKey="Renoir, Thibault" sort="Renoir, Thibault" uniqKey="Renoir T" first="Thibault" last="Renoir">Thibault Renoir</name>
<affiliation wicri:level="4"><nlm:affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia. Electronic address: thibault.renoir@unimelb.edu.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Argyropoulos, Andrew" sort="Argyropoulos, Andrew" uniqKey="Argyropoulos A" first="Andrew" last="Argyropoulos">Andrew Argyropoulos</name>
<affiliation wicri:level="4"><nlm:affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chevarin, Caroline" sort="Chevarin, Caroline" uniqKey="Chevarin C" first="Caroline" last="Chevarin">Caroline Chevarin</name>
<affiliation wicri:level="1"><nlm:affiliation>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris</wicri:regionArea>
<wicri:noRegion>75013 Paris</wicri:noRegion>
<wicri:noRegion>75013 Paris</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lanfumey, Laurence" sort="Lanfumey, Laurence" uniqKey="Lanfumey L" first="Laurence" last="Lanfumey">Laurence Lanfumey</name>
<affiliation wicri:level="1"><nlm:affiliation>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris</wicri:regionArea>
<wicri:noRegion>75013 Paris</wicri:noRegion>
<wicri:noRegion>75013 Paris</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hannan, Anthony J" sort="Hannan, Anthony J" uniqKey="Hannan A" first="Anthony J" last="Hannan">Anthony J. Hannan</name>
<affiliation wicri:level="4"><nlm:affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Pharmacology, biochemistry, and behavior</title>
<idno type="eISSN">1873-5177</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid (antagonists & inhibitors)</term>
<term>3,4-Dihydroxyphenylacetic Acid (metabolism)</term>
<term>Animals</term>
<term>Disease Models, Animal</term>
<term>Dopamine (metabolism)</term>
<term>Dopamine Uptake Inhibitors (pharmacology)</term>
<term>Dopamine Uptake Inhibitors (therapeutic use)</term>
<term>Female</term>
<term>Huntington Disease (drug therapy)</term>
<term>Huntington Disease (genetics)</term>
<term>Huntington Disease (metabolism)</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Mice, Inbred CBA</term>
<term>Mice, Transgenic</term>
<term>Receptors, Dopamine D1 (antagonists & inhibitors)</term>
<term>Receptors, Dopamine D1 (metabolism)</term>
<term>Sex Characteristics</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acide 3,4-dihydroxy-benzèneacétique (antagonistes et inhibiteurs)</term>
<term>Acide 3,4-dihydroxy-benzèneacétique (métabolisme)</term>
<term>Animaux</term>
<term>Caractères sexuels</term>
<term>Dopamine (métabolisme)</term>
<term>Femelle</term>
<term>Inhibiteurs de la capture de la dopamine (pharmacologie)</term>
<term>Inhibiteurs de la capture de la dopamine (usage thérapeutique)</term>
<term>Maladie de Huntington (génétique)</term>
<term>Maladie de Huntington (métabolisme)</term>
<term>Maladie de Huntington (traitement médicamenteux)</term>
<term>Modèles animaux de maladie humaine</term>
<term>Mâle</term>
<term>Récepteur dopamine D1 (antagonistes et inhibiteurs)</term>
<term>Récepteur dopamine D1 (métabolisme)</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
<term>Souris de lignée CBA</term>
<term>Souris transgéniques</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid</term>
<term>Receptors, Dopamine D1</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid</term>
<term>Dopamine</term>
<term>Receptors, Dopamine D1</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Dopamine Uptake Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Uptake Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Acide 3,4-dihydroxy-benzèneacétique</term>
<term>Récepteur dopamine D1</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Maladie de Huntington</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Acide 3,4-dihydroxy-benzèneacétique</term>
<term>Dopamine</term>
<term>Maladie de Huntington</term>
<term>Récepteur dopamine D1</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de la capture de la dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie de Huntington</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de la capture de la dopamine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Mice, Inbred CBA</term>
<term>Mice, Transgenic</term>
<term>Sex Characteristics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Caractères sexuels</term>
<term>Femelle</term>
<term>Modèles animaux de maladie humaine</term>
<term>Mâle</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
<term>Souris de lignée CBA</term>
<term>Souris transgéniques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Using the R6/1 transgenic mouse model of Huntington's disease (HD), we have recently shown that acute administration with the dopamine-norepinephrine reuptake inhibitor bupropion was able to rescue depressive-like behaviours in female HD mice at 12weeks of age.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F10 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001F10 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:25316307 |texte= Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:25316307" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |